AstraZeneca will partner with VaxEquity for the discovery and development of a self-amplifying RNA (saRNA) therapeutics platform.
List view / Grid view
Imperial College London
The largest placebo-controlled psychedelics study to date concluded that the psychological benefits of microdoses of psychedelics are likely due to the placebo effect.
IL-6 receptor antagonists tocilizumab and sarilumab have a significant impact on COVID-19 patient mortality, a study has shown.
The UK Government is supporting the development of COVID-19 vaccines, including two innovative UK vaccine candidates. In this article, we describe the history of these candidates and introduce innovative small and medium enterprises (SMEs) and national capabilities that are working to combat the current pandemic and improve the UK’s vaccine…
The UK government hopes to expedite the development of a COVID-19 vaccine by investing £33.6 million in the first phase of establishing human challenge trials.
Prime Minister Boris Johnson visited the construction site of the VMIC and met scientists and engineers at the forefront of the UK’s COVID-19 response.
A trial has shown that COVID-19 patients treated with the steroid hydrocortisone had a 93 percent chance of a better outcome from the coronavirus.
The government has entered partnerships with Pfizer and Valneva to secure doses of several promising COVID-19 vaccines and secured COVID-19 neutralising antibody treatments from AstraZeneca.
A Phase I clinical trial to test Imperial College London's COVID-19 vaccine candidate has been initiated, with the first patient dosed.
A clinical trial is set to investigate whether a molecule known as TRV027 is effective at preventing lung damage and the formation of blood clots in COVID-19 patients.
The UK Bioindustry Association industry-led vaccine manufacturing group has welcomed a £14 million investment to support COVID-19 vaccine manufacturing.
The UK government has announced that funding will be given to clinical trials to test a COVID-19 vaccine, with one study beginning tomorrow.
A partnership between Imperial College London and CPI will enable the two organisations to translate research into products and services for pharma.